# Solventum Corp: overview

SOLV · NYSE · CIK 1964738 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/solv.md) · [Financials](/companies/solv/financials.md) · [Filings](/companies/solv/filings.md) · [Insiders](/companies/solv/insiders.md)

Latest reported revenue: [$2.21bn](/filings/0001964738-26-000047.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0001964738-26-000047).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,082](/filings/0001964738-25-000091.md) | [2,075 d](/filings/0001964738-26-000007.md) | [2,070](/filings/0001964738-26-000024.md) | [2,161](/filings/0001964738-26-000047.md) | [2,096](/filings/0001964738-25-000091.md) | [1,998 d](/filings/0001964738-26-000007.md) | [2,007](/filings/0001964738-26-000024.md) | [2,209](/filings/0001964738-26-000047.md) |
| Gross margin | % | [56.0%](/filings/0001964738-25-000091.md) | [53.9% d](/filings/0001964738-26-000007.md) | [53.8%](/filings/0001964738-26-000024.md) | [54.4%](/filings/0001964738-26-000047.md) | [54.2%](/filings/0001964738-25-000091.md) | [51.4% d](/filings/0001964738-26-000007.md) | [54.7%](/filings/0001964738-26-000024.md) | [58.2%](/filings/0001964738-26-000047.md) |
| Operating margin | % | [13.2%](/filings/0001964738-25-000091.md) | [6.6% d](/filings/0001964738-26-000007.md) | [7.3%](/filings/0001964738-26-000024.md) | [9.9%](/filings/0001964738-26-000047.md) | [80.6%](/filings/0001964738-25-000091.md) | [6.2% d](/filings/0001964738-26-000007.md) | [4.0%](/filings/0001964738-26-000024.md) | [8.2%](/filings/0001964738-26-000047.md) |
| Net margin | % | [5.9%](/filings/0001964738-25-000091.md) | [1.5% d](/filings/0001964738-26-000007.md) | [6.6%](/filings/0001964738-26-000024.md) | [4.2%](/filings/0001964738-26-000047.md) | [60.4%](/filings/0001964738-25-000091.md) | [3.2% d](/filings/0001964738-26-000007.md) | [0.6%](/filings/0001964738-26-000024.md) | [4.2%](/filings/0001964738-26-000047.md) |
| Diluted EPS | $ per share | [0.70](/filings/0001964738-25-000091.md) | not reported | [0.78](/filings/0001964738-26-000024.md) | [0.51](/filings/0001964738-26-000047.md) | [7.22](/filings/0001964738-25-000091.md) | not reported | [0.07](/filings/0001964738-26-000024.md) | [0.53](/filings/0001964738-26-000047.md) |
| Free cash flow | $m | [76.0 d](/filings/0001964738-25-000091.md) | [92.0 d](/filings/0001964738-26-000007.md) | [(80.0)](/filings/0001964738-26-000024.md) | [59.0 d](/filings/0001964738-26-000047.md) | [(21.0) d](/filings/0001964738-25-000091.md) | [32.0 d](/filings/0001964738-26-000007.md) | [(273)](/filings/0001964738-26-000024.md) | [144 d](/filings/0001964738-26-000047.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [8,130](/filings/0001964738-25-000019.md) | [8,197](/filings/0001964738-26-000007.md) | [8,254](/filings/0001964738-26-000007.md) | [8,325](/filings/0001964738-26-000007.md) |
| Gross margin | % | [57.7%](/filings/0001964738-25-000019.md) | [57.3%](/filings/0001964738-26-000007.md) | [55.6%](/filings/0001964738-26-000007.md) | [53.5%](/filings/0001964738-26-000007.md) |
| Operating margin | % | [20.8%](/filings/0001964738-25-000019.md) | [20.6%](/filings/0001964738-26-000007.md) | [12.6%](/filings/0001964738-26-000007.md) | [26.2%](/filings/0001964738-26-000007.md) |
| Net margin | % | [16.5%](/filings/0001964738-25-000019.md) | [16.4%](/filings/0001964738-26-000007.md) | [5.8%](/filings/0001964738-26-000007.md) | [18.7%](/filings/0001964738-26-000007.md) |
| Diluted EPS | $ per share | [7.78](/filings/0001964738-25-000019.md) | [7.79](/filings/0001964738-26-000007.md) | [2.76](/filings/0001964738-26-000007.md) | [8.88](/filings/0001964738-26-000007.md) |
| Free cash flow | $m | [1,428](/filings/0001964738-25-000019.md) | [1,625](/filings/0001964738-26-000007.md) | [805](/filings/0001964738-26-000007.md) | [(10.0)](/filings/0001964738-26-000007.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/solv/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Independent Franchise Partners LLP](/funds/1483866.md) | 2026-06-30 | $1.25bn | 16,170,038 |  | Added +436,543 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $753.1m | 9,761,863 |  | Reduced −717,109 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $742.6m | 9,624,829 |  | Added +22,880 |
| [TRIAN FUND MANAGEMENT, L.P.](/funds/1345471.md) | 2026-06-30 | $635.5m | 8,236,753 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $488.3m | 6,328,641 |  | Reduced −61,723 |
| [Davis Selected Advisers](/funds/1036325.md) | 2026-06-30 | $486.7m | 6,307,729 |  | Reduced −22,596 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $435.1m | 5,639,230 |  | Reduced −768,250 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $378.3m | 4,910,624 |  | Added +158,364 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $311.5m | 4,037,963 |  | Added +123,872 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $255.4m | 3,309,915 |  | Reduced −479,968 |

## Recent filings

[All 253 filings](/companies/solv/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 17:27 ET | [10-Q](/filings/0001964738-26-000047.md) | Quarterly report, period 2026-06-30 | 0001964738-26-000047 |
| 2026-08-05 | 16:17 ET | [8-K](/filings/0001964738-26-000045.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001964738-26-000045 |
| 2026-08-05 | 16:11 ET | [8-K](/filings/0001964738-26-000043.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001964738-26-000043 |
| 2026-07-20 | 16:15 ET | [8-K](/filings/0001964738-26-000038.md) | 5.02 Departure or appointment of officers or directors | 0001964738-26-000038 |
| 2026-06-05 | 16:25 ET | [8-K](/filings/0001964738-26-000036.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001964738-26-000036 |
| 2026-05-27 | 16:23 ET | [8-K](/filings/0001964738-26-000031.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001964738-26-000031 |
| 2026-05-20 | 16:14 ET | [8-K](/filings/0001964738-26-000027.md) | 5.07 Shareholder vote results | 0001964738-26-000027 |
| 2026-05-05 | 17:29 ET | [10-Q](/filings/0001964738-26-000024.md) | Quarterly report, period 2026-03-31 | 0001964738-26-000024 |
| 2026-05-05 | 16:08 ET | [8-K](/filings/0001964738-26-000022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001964738-26-000022 |
| 2026-03-27 | 16:15 ET | [DEF 14A](/filings/0001964738-26-000017.md) | Proxy statement, period 2025-12-31 | 0001964738-26-000017 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001964738-26-000007.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0e078746-4e3f-4539-be37-f55d1b16d5f8)

## About the filer

- CIK: 1964738
- Tickers: SOLV
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.